Immunome (NASDAQ:IMNM) Sees Strong Trading Volume

Immunome, Inc. (NASDAQ:IMNM) saw strong trading volume on Thursday . 662,051 shares changed hands during mid-day trading, a decline of 14% from the previous session’s volume of 769,601 shares.The stock last traded at $15.99 and had previously closed at $15.50.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on IMNM shares. Piper Sandler lowered their price objective on Immunome from $27.00 to $23.00 and set an “overweight” rating for the company in a research note on Tuesday, August 13th. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price target on shares of Immunome in a research report on Tuesday, August 13th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $29.00.

Immunome Stock Down 2.0 %

The stock has a market capitalization of $898.94 million, a P/E ratio of -1.99 and a beta of 1.77. The business has a fifty day moving average price of $14.51 and a 200-day moving average price of $16.24.

Immunome (NASDAQ:IMNM) last posted its earnings results on Monday, August 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.11). The company had revenue of $2.36 million for the quarter, compared to the consensus estimate of $2.62 million. Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. On average, equities analysts expect that Immunome, Inc. will post -1.92 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Jean Jacques Bienaime bought 7,000 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was acquired at an average cost of $13.94 per share, for a total transaction of $97,580.00. Following the purchase, the director now owns 16,615 shares in the company, valued at $231,613.10. The acquisition was disclosed in a filing with the SEC, which is available through this link. In other news, Director Jean Jacques Bienaime purchased 7,000 shares of the business’s stock in a transaction on Friday, August 16th. The stock was acquired at an average cost of $13.94 per share, for a total transaction of $97,580.00. Following the purchase, the director now directly owns 16,615 shares in the company, valued at approximately $231,613.10. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Jack Higgins sold 3,524 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $13.93, for a total transaction of $49,089.32. Following the completion of the transaction, the insider now directly owns 16,000 shares in the company, valued at approximately $222,880. The disclosure for this sale can be found here. 8.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Immunome

Institutional investors have recently bought and sold shares of the stock. Quest Partners LLC purchased a new position in shares of Immunome during the 2nd quarter valued at about $81,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Immunome in the second quarter worth approximately $97,000. Arizona State Retirement System increased its stake in shares of Immunome by 9.2% in the second quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock worth $131,000 after purchasing an additional 918 shares in the last quarter. EntryPoint Capital LLC increased its stake in shares of Immunome by 21,864.0% in the first quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock worth $136,000 after purchasing an additional 5,466 shares in the last quarter. Finally, Jump Financial LLC bought a new stake in shares of Immunome during the 4th quarter valued at $172,000. 44.58% of the stock is owned by institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.